Phase III clinical trials using 40mg Copaxone three times a week on 1400 Multiple Sclerosis patients in 155 sites worldwide, resulted in a 34.4% reduction in relapse rates.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000757401
Teva’s Copaxone prevents MS relapses
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.